GLP-1 & Weight Loss

Mounjaro, Ozempic and Wegovy: What Are GLP-1 Weight-Loss Medicines?

Evidence-checked Published 16 July 2026·2 min read
G&

The short version

Three trending names, three different prescription medicines. Here is what they actually do inside your body, how much weight people really lose in trials, and why the right choice depends on your health rather than a reel.

Three names keep showing up in your feed. Mounjaro. Ozempic. Wegovy. They turn up in celebrity gossip, gym chat and endless before-and-after reels, usually treated as one magic pen you could pick up like a protein bar. The reality is more interesting, and worth two minutes of your time.

Look at the ingredient first. Mounjaro is tirzepatide. Ozempic and Wegovy are both semaglutide, the same molecule under two names. These medicines copy a signal your own gut already sends. After you eat, your intestine releases hormones that tell your brain you have had enough. Semaglutide mimics one of them, called GLP-1. Tirzepatide mimics two, adding a second called GIP. So you feel full sooner, eat less, your blood sugar steadies, and food leaves your stomach more slowly. It turns up a system your body already runs.

The brand name can mislead you. The same molecule might be approved for diabetes in one box and for weight management in another, at different doses, in different countries. What is legal, available and sensibly priced in India this month is something only a clinician can confirm at the time of prescribing. A caption cannot.

Do they work? The trial numbers are strong. In a large study of adults with overweight or obesity but no diabetes, those on semaglutide with lifestyle support lost an average of 14.9 percent of their body weight over 68 weeks. A 2025 trial compared tirzepatide with semaglutide directly in adults with obesity, and at 72 weeks the tirzepatide group lost more on average. Watch the word average. Some people lose far less. Some cannot tolerate the drug at all. A trial describes a crowd, and you are one person.

That gap is why a real consultation asks questions a short video never will. Do you have diabetes? Any sign of sleep apnoea? Are you on other medicines that affect blood sugar? Any history of pancreatitis or gallbladder trouble? Any chance you are pregnant? These answers change whether a medicine is safe for you and which one fits.

The side effects deserve the same honesty. Nausea, vomiting, constipation and diarrhoea are common, and they often show up as the dose climbs. Rarer problems can be serious. Persistent vomiting, severe abdominal pain or dehydration are reasons to call a doctor, not to push through. Demand has also outrun supply, and the World Health Organization has warned that fake and substandard copies are circulating. Buying a pen from an unverified seller is a gamble with your body.

These drugs work best inside a plan. That might mean blood tests, a sleep check, nutrition support, follow-up appointments, and an honest talk about whether medicine is even the right tool for you. The point was never a number on the scale. It is health you can hold on to.

Key message

GLP-1 medicines can genuinely help selected people with obesity or diabetes. They are prescription treatments that work best with clinical supervision and long-term care.

The receipts: peer-reviewed & official sources

Every claim in this article traces back to these 3 sources.

  1. WHO GLP-1 questions and answers
  2. Semaglutide trial in NEJM
  3. Tirzepatide versus semaglutide trial in NEJM
This article explains evidence. It does not diagnose, prescribe, or replace a consultation with a qualified clinician. A registered doctor reviews articles before final publication.

Still have a question?

Ask our evidence tool. It only answers from our published, source-checked articles.

Ask the Evidence